Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II trial of allogeneic dual CD123/33 CARCIK cells in relapsed/refractory AML and BPDCN
2025-524977-18-00Phase 2Authorised
- Sponsor
- Fondazione Matilde Tettamanti
- Start
- Jul 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CARCIK CD123/33 in acute myeloid leukemia (AML) and Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by Fondazione Matilde Tettamanti. Primary endpoints: Rate of enrolled patients that receive CARCIK-CD123/33 infusion, Dose-limiting toxicity (DLT) rate within 28 days and 1 more. Planned start Jul 2026; status: authorised.
02
Drugs
CARCIK CD123/33
03
Conditions
acute myeloid leukemia (AML)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on 2025-524977-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524977-18-00.